Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Autoimmune Disorders

Free Subscription Articles published in Neurology Retrieve available abstracts of 337 articles: HTML format

Single Articles

August 2024
1. 
   Characterization Profiles of ANCA-associated Vasculitis With Neurological Manifestations (P7-14.007).
   Neurology. 2024;103:e209640.
   PubMed    
   
   
   
2. 
   Artificial Intelligence-Based Ocular Motor Biomarkers for Myasthenia Gravis Diagnosis (P10-11.016).
   Neurology. 2024;103:e209639.
   PubMed    
   
   
   
3. MAYCOCK TJ, Rossor T, Vanegas M, Gringras P, et al
   Child Neurology: Common Occurrence of Narcolepsy Type 1 and Myasthenia Gravis.
   Neurology. 2024;103:e209598.
   PubMed     Abstract available
   
   
   
4. SASTRE-GARRIGA J, Vidal-Jordana A, Toosy AT, Enzinger C, et al
   Value of Optic Nerve MRI in Multiple Sclerosis Clinical Management: A MAGNIMS Position Paper and Future Perspectives.
   Neurology. 2024;103:e209677.
   PubMed     Abstract available
   
   
   
5. WILLIAMS MJ, Amezcua L, Cohan SL, Cohen JA, et al
   Efficacy of Ofatumumab and Teriflunomide in Patients With Relapsing MS From Racial/Ethnic Minority Groups: ASCLEPIOS I/II Subgroup Analyses.
   Neurology. 2024;103:e209610.
   PubMed     Abstract available
   
   
   July 2024
6. PFEUFFER S, Wolff S, Aslan D, Rolfes L, et al
   Association of Clinical Relapses With Disease Outcomes in Multiple Sclerosis Patients Older Than 50 Years.
   Neurology. 2024;103:e209574.
   PubMed     Abstract available
   
   
   
7. GRANGEON L, Boulouis G, Capron J, Bala F, et al
   Cerebral Amyloid Angiopathy-Related Inflammation and Biopsy-Positive Primary Angiitis of the CNS: A Comparative Study.
   Neurology. 2024;103:e209548.
   PubMed     Abstract available
   
   
   
8. GAVAZZI F, Vaia Y, Woidill S, Formanowski B, et al
   Nonverbal Cognitive Skills in Children With Aicardi Goutieres Syndrome.
   Neurology. 2024;103:e209541.
   PubMed     Abstract available
   
   
   
9. CICCARELLI O, Barkhof F, Calabrese M, De Stefano N, et al
   Using the Progression Independent of Relapse Activity Framework to Unveil the Pathobiological Foundations of Multiple Sclerosis.
   Neurology. 2024;103:e209444.
   PubMed     Abstract available
   
   
   
10. MADSEN MA, Povazan M, Wiggermann V, Lundell H, et al
    Association of Cortical Lesions With Regional Glutamate, GABA, N-Acetylaspartate, and Myoinositol Levels in Patients With Multiple Sclerosis.
    Neurology. 2024;103:e209543.
    PubMed     Abstract available
    
    
    June 2024
11. KAMINSKI HJ, Kusner LL, Cutter GR, Le Panse R, et al
    Does Surgical Removal of the Thymus Have Deleterious Consequences?
    Neurology. 2024;102:e209482.
    PubMed     Abstract available
    
    
    
12. PALLADINO R, Monasta L
    Estimating the Prevalence and Burden of Multiple Sclerosis in China Using the Global Burden of Disease Study: Challenges and Future Directions.
    Neurology. 2024;102:e209521.
    PubMed    
    
    
    
13. ZHANG C, Liu W, Wang L, Wang F, et al
    Prevalence and Burden of Multiple Sclerosis in China, 1990-2019: Findings From the Global Burden of Disease Study 2019.
    Neurology. 2024;102:e209351.
    PubMed     Abstract available
    
    
    May 2024
14. CACCIAGUERRA L, Abdel-Mannan O, Champsas D, Mankad K, et al
    Radiologic Lag and Brain MRI Lesion Dynamics During Attacks in MOG Antibody-Associated Disease.
    Neurology. 2024;102:e209303.
    PubMed     Abstract available
    
    
    
15. SILBERMANN E, Spain RI
    Serum Neurofilament Light Chain for Multiple Sclerosis Relapses: Too Little Too Late?
    Neurology. 2024;102:e209456.
    PubMed    
    
    
    
16. FOX RJ, Cree BAC, de Seze J, Gold R, et al
    Temporal Relationship Between Serum Neurofilament Light Chain and Radiologic Disease Activity in Patients With Multiple Sclerosis.
    Neurology. 2024;102:e209357.
    PubMed     Abstract available
    
    
    
17. VALKO Y, Wirth MA, Fierz FC, Schesny MK, et al
    Accuracy of Repetitive Ocular Vestibular-Evoked Myogenic Potentials to Diagnose Myasthenia Gravis in Patients With Ptosis or Diplopia.
    Neurology. 2024;102:e209395.
    PubMed     Abstract available
    
    
    
18. LIAO J, Lu Y, Lu Y, Huang Y, et al
    Cardiopulmonary Coupling Spectrogram as an Ambulatory Method for Assessing Sleep Disorders in Patients With Autoimmune Encephalitis.
    Neurology. 2024;102:e209302.
    PubMed     Abstract available
    
    
    
19. MICHAELSON NM
    Right Brain: The Unraveling.
    Neurology. 2024;102:e209492.
    PubMed     Abstract available
    
    
    
20. VYAS MV, Kapral MK, Alonzo R, Fang J, et al
    Proportion of Life Spent in Canada and the Incidence of Multiple Sclerosis in Permanent Immigrants.
    Neurology. 2024;102:e209350.
    PubMed     Abstract available
    
    
    
21. TANG A, Yoshida K, Lahey H, Wilcox DR, et al
    Herpes Simplex Virus Encephalitis in Patients With Autoimmune Conditions or Exposure to Immunomodulatory Medications.
    Neurology. 2024;102:e209297.
    PubMed     Abstract available
    
    
    April 2024
22. ZOUVELOU V, Petrou EM, Strataki E, Vasileiou V, et al
    Pearls & Oy-sters: Thyroid-Associated Ophthalmopathy and Transient Neuromuscular Junction Disorder Due to Graves Disease.
    Neurology. 2024;102:e209282.
    PubMed     Abstract available
    
    
    
23. DEMORTIERE S, Joubert B, Benaiteau M, Hilezian F, et al
    Anti-IgLON5 Disease With Inaugural Bilateral Neuropapillitis.
    Neurology. 2024;102:e209284.
    PubMed    
    
    
    
24. MOEHLMAN M, Kornbluh AB
    Teaching NeuroImage: Anti-NMDA Receptor Encephalitis Presenting With Cerebellitis in a Pediatric Patient.
    Neurology. 2024;102:e209259.
    PubMed    
    
    
    
25. 
    Adding the Optic Nerve in Multiple Sclerosis Diagnostic Criteria: A Longitudinal, Prospective, Multicenter Study.
    Neurology. 2024;102:e209214.
    PubMed    
    
    
    
26. OYAMA M, Holzer MT, Ohnuki Y, Saito Y, et al
    Pathologic Features of Anti-Ku Myositis.
    Neurology. 2024;102:e209268.
    PubMed     Abstract available
    
    
    
27. OLIVE-CIRERA G, Bruijstens AL, Fonseca EG, Chen LW, et al
    MOG Antibodies Restricted to CSF in Children With Inflammatory CNS Disorders.
    Neurology. 2024;102:e209199.
    PubMed     Abstract available
    
    
    
28. SPELMAN T, Simoneau G, Hyde R, Kuhelj R, et al
    Comparative Effectiveness of Natalizumab, Fingolimod, and Injectable Therapies in Pediatric-Onset Multiple Sclerosis: A Registry-Based Study.
    Neurology. 2024;102:e208114.
    PubMed     Abstract available
    
    
    
29. TOGNI CL, Frontzek K, Schubring-Giese M, Imbach LL, et al
    Posttransplant Anti-GABA(A) Receptor Antibody-Associated Autoimmune Encephalitis.
    Neurology. 2024;102:e209245.
    PubMed    
    
    
    
30. THAKOLWIBOON S, Dubey D
    Redefining Patient Evaluation in Anti-IgLON5 Disease: Anti-IgLON5 Disease Composite Score.
    Neurology. 2024;102:e209213.
    PubMed    
    
    
    
31. GAIG C, Gruter T, Heidbreder A, Sabater L, et al
    Development of a Composite Score for the Clinical Assessment of Anti-IgLON5 Disease.
    Neurology. 2024;102:e208101.
    PubMed     Abstract available
    
    
    
32. KOTHAPALLI NP, Chompoopong P, McKeon A, Dubey D, et al
    Teaching Video NeuroImage: Adaptor-Related Protein-Complex-3 Subunit beta-2 Immunoglobulin-G-Associated Autoimmune Ataxia.
    Neurology. 2024;102:e209257.
    PubMed    
    
    
    
33. AGYEI P, Chen M, Guo Y, Perez CA, et al
    Pearls & Oy-sters: KLHL11 IgG Paraneoplastic-Associated Hearing Loss and Rhombencephalitis in a Woman With Metastatic Mullerian Tumor.
    Neurology. 2024;102:e209187.
    PubMed     Abstract available
    
    
    March 2024
34. YOUNG A, Johnston JL
    Pearls & Oy-sters: Ocular Myasthenia Gravis: Central Ocular Motor Signs and Unilateral Visual Loss Caused by the Great Neuro-Ophthalmologic Impersonator.
    Neurology. 2024;102:e209260.
    PubMed     Abstract available
    
    
    
35. AOTSUKA Y, Misawa S, Suichi T, Shibuya K, et al
    Prevalence, Clinical Profiles, and Prognosis of CIDP in Japanese Nationwide Survey: Analyses of 1,257 Diagnosis-Confirmed Patients.
    Neurology. 2024;102:e209130.
    PubMed     Abstract available
    
    
    
36. MARRIE RA, Salter A
    Off-Road Testing: Outcome Reporting Bias in Multiple Sclerosis Trials.
    Neurology. 2024;102:e208099.
    PubMed    
    
    
    
37. LEMMENS CMC, van Amerongen S, Strijbis EM, Killestein J, et al
    Outcome Reporting Bias in Clinical Trials Researching Disease-Modifying Therapy in Patients With Multiple Sclerosis.
    Neurology. 2024;102:e208032.
    PubMed     Abstract available
    
    
    
38. BOURDETTE D, Wooliscroft L
    The Challenges of Treating Late-Onset Multiple Sclerosis.
    Neurology. 2024;102:e209146.
    PubMed    
    
    
    
39. MOURESAN EF, Mentesidou E, Berglund A, Mckay KA, et al
    Clinical Characteristics and Long-Term Outcomes of Late-Onset Multiple Sclerosis: A Swedish Nationwide Study.
    Neurology. 2024;102:e208051.
    PubMed     Abstract available
    
    
    
40. 
    Characteristics, Prevalence, and Clinical Relevance of Juxtacortical Paramagnetic Rims in Patients With Multiple Sclerosis.
    Neurology. 2024;102:e209252.
    PubMed    
    
    
    
41. SALTER A, Lancia S, Kowalec K, Fitzgerald KC, et al
    Investigating the Prevalence of Comorbidity in Multiple Sclerosis Clinical Trial Populations.
    Neurology. 2024;102:e209135.
    PubMed     Abstract available
    
    
    
42. CHARD DT
    Chronically Active Lesions as a Trial Outcome in Multiple Sclerosis: A New Perspective on an Old Foe.
    Neurology. 2024;102:e209246.
    PubMed    
    
    
    
43. ARNOLD DL, Elliott C, Martin EC, Hyvert Y, et al
    Effect of Evobrutinib on Slowly Expanding Lesion Volume in Relapsing Multiple Sclerosis: A Post Hoc Analysis of a Phase 2 Trial.
    Neurology. 2024;102:e208058.
    PubMed     Abstract available
    
    
    
44. PAPP V, Magyari M, Moller S, Sellebjerg F, et al
    Mortality of the Danish Nationwide AQP4 Antibody-Seropositive Neuromyelitis Optica Spectrum Disorder Patient Cohort.
    Neurology. 2024;102:e209147.
    PubMed     Abstract available
    
    
    February 2024
45. MORGAN A, Li Y, Thompson NR, Milinovich A, et al
    Longitudinal Disability, Cognitive Impairment, and Mood Symptoms in Patients With Anti-NMDA Receptor Encephalitis.
    Neurology. 2024;102:e208019.
    PubMed     Abstract available
    
    
    
46. RADZIK AM, Amezcua L, Anderson A, Gilmore S, et al
    Disparities by Race in Pregnancy Care and Clinical Outcomes in Women With Multiple Sclerosis: A Diverse Multicenter Cohort.
    Neurology. 2024;102:e208100.
    PubMed     Abstract available
    
    
    
47. BRANCH A, Nuaaman MM, Appleton CT, Connaughton DM, et al
    Teaching NeuroImage: Extensive Brainstem and Striatal Involvement in Neuropsychiatric Systemic Lupus Erythematosus.
    Neurology. 2024;102:e209153.
    PubMed    
    
    
    
48. GALBUSERA R, Bahn E, Weigel M, Cagol A, et al
    Characteristics, Prevalence, and Clinical Relevance of Juxtacortical Paramagnetic Rims in Patients With Multiple Sclerosis.
    Neurology. 2024;102:e207966.
    PubMed     Abstract available
    
    
    
49. WU J, Guo K, Liu J
    Partially Reversible FLAIR Hyperintensity Along the Brainstem Surface in Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy.
    Neurology. 2024;102:e208064.
    PubMed     Abstract available
    
    
    
50. NG HS, Zhu F, Zhao Y, Yao S, et al
    Adverse Events Associated With Disease-Modifying Drugs for Multiple Sclerosis.
    Neurology. 2024;102:e208006.
    PubMed     Abstract available
    
    
    
51. BELLUCCI M, Castellano C, Marinelli L, Garbarino L, et al
    Patient With Rigidity and Fasciculations.
    Neurology. 2024;102:e208110.
    PubMed     Abstract available
    
    
    
52. BRIDGE F, Brotherton J, Stankovich J, Sanfilippo PG, et al
    Risk of Cervical Abnormalities for Women With Multiple Sclerosis Treated With Moderate-Efficacy and High-Efficacy Disease-Modifying Therapies.
    Neurology. 2024;102:e208059.
    PubMed     Abstract available
    
    
    January 2024
53. GIBSON S, Mcgraw C
    Teaching NeuroImage: Cryptococcus in a Woman With Multiple Sclerosis on Fingolimod.
    Neurology. 2024;102:e208027.
    PubMed     Abstract available
    
    
    
54. ANTOZZI C, Guptill J, Bril V, Gamez J, et al
    Safety and Efficacy of Nipocalimab in Patients With Generalized Myasthenia Gravis.
    Neurology. 2024;102:e207937.
    PubMed     Abstract available
    
    
    
55. MCGINLEY MP, Harvey T, Lopez R, Ontaneda D, et al
    Geographic Disparities in Access to Neurologists and Multiple Sclerosis Care in the United States.
    Neurology. 2024;102:e207916.
    PubMed     Abstract available
    
    
    
56. HABIB AA, Sacks N, Cool C, Durgapal S, et al
    Hospitalizations and Mortality From Myasthenia Gravis.
    Neurology. 2024;102:e207863.
    PubMed     Abstract available
    
    
    
57. LANGER-GOULD A, Sotirchos ES, Bourdette D
    Rituximab for Multiple Sclerosis.
    Neurology. 2024;102:e208063.
    PubMed     Abstract available
    
    
    
58. GALETTA S, Brownlee W
    Assignment Completed.
    Neurology. 2024;102:e207913.
    PubMed     Abstract available
    
    
    
59. TUR C, Rocca MA
    Progression Independent of Relapse Activity in Multiple Sclerosis.
    Neurology. 2024;102:e207936.
    PubMed     Abstract available
    
    
    
60. VIDAL-JORDANA A, Rovira A, Calderon W, Arrambide G, et al
    Adding the Optic Nerve in Multiple Sclerosis Diagnostic Criteria.
    Neurology. 2024;102:e200805.
    PubMed     Abstract available
    
    
    
61. CAGOL A, Benkert P, Melie-Garcia L, Schaedelin SA, et al
    Association of Spinal Cord Atrophy and Brain Paramagnetic Rim Lesions With Progression Independent of Relapse Activity in People With MS.
    Neurology. 2024;102:e207768.
    PubMed     Abstract available
    
    
    
62. VLAHOVIC L, McDonald J, Hinman J, Tomczak A, et al
    Prevalence, Demographic, and Clinical Factors Associated With Cognitive Dysfunction in Patients With Neuromyelitis Optica Spectrum Disorder.
    Neurology. 2024;102:e207965.
    PubMed     Abstract available
    
    
    
63. ALKABIE S, Gray MT, Lau JC, Barra L, et al
    Teaching NeuroImage: Unilateral Primary Angiitis of the CNS.
    Neurology. 2024;102:e208018.
    PubMed     Abstract available
    
    
    December 2023
64. ROLLOT F, Uhry Z, Dantony E, Vukusic S, et al
    Comparison of 2 Methods for Estimating Multiple Sclerosis-Related Mortality.
    Neurology. 2023;101:e2483-e2496.
    PubMed     Abstract available
    
    
    
65. SUNSHINE A, Mandle QJ, Cabal Herrera AM, Zapanta B, et al
    Pearls & Oy-sters: Leber Hereditary Optic Neuropathy-Plus Masquerading as Neuromyelitis Optica Spectrum Disorder in a 2-Year-Old Child.
    Neurology. 2023;101:e2585-e2588.
    PubMed     Abstract available
    
    
    
66. GUINEBRETIERE O, Nedelec T, Gantzer L, Lekens BB, et al
    Association Between Diseases and Symptoms Diagnosed in Primary Care and the Subsequent Specific Risk of Multiple Sclerosis.
    Neurology. 2023 Dec 5:10.1212/WNL.0000000000207981.
    PubMed     Abstract available
    
    
    November 2023
67. LI X, Stitt D, Lanzino G, Giannini C, et al
    Teaching NeuroImage: Pachymeningitis and Aortitis as the Initial Presentation of Granulomatosis With Polyangiitis.
    Neurology. 2023;101:979-980.
    PubMed    
    
    
    October 2023
68. SRIVASTAVA I, Van Haren K
    Immunotherapy in Autoimmune Encephalitis: So Many Options, So Few Guidelines.
    Neurology. 2023 Oct 25:10.1212/WNL.0000000000208026.
    PubMed    
    
    
    
69. BOURDETTE D, Silbermann E
    What Are the Risks of Guillain-Barre Syndrome Following SARS-CoV-2 Infection and COVID-19 Vaccination?
    Neurology. 2023 Oct 18:10.1212/WNL.0000000000207998.
    PubMed    
    
    
    
70. BISHARA H, Arbel A, Barnett-Griness O, Bloch S, et al
    Association Between Guillain-Barre Syndrome and COVID-19 Infection and Vaccination: A Population-Based Nested Case-Control Study.
    Neurology. 2023 Oct 18:10.1212/WNL.0000000000207900.
    PubMed     Abstract available
    
    
    
71. YANG JH, Liu EN, Nguyen L, Dunn-Pirio A, et al
    Survival Analysis of Immunotherapy Effects on Relapse Rate in Pediatric and Adult Autoimmune Encephalitis.
    Neurology. 2023 Oct 12:10.1212/WNL.0000000000207746.
    PubMed     Abstract available
    
    
    
72. GUASP M, Dalmau J
    Searching for Neuronal Antibodies in Psychiatric Diseases: Uncertain Findings and Implications.
    Neurology. 2023;101:656-660.
    PubMed     Abstract available
    
    
    
73. SOTIRCHOS ES, Hu C, Smith MD, Lord HN, et al
    Agreement Between Published Reference Resources for Neurofilament Light Chain Levels in People With Multiple Sclerosis.
    Neurology. 2023 Oct 10:10.1212/WNL.0000000000207957.
    PubMed     Abstract available
    
    
    
74. LE VU S, Bertrand M, Botton J, Jabagi MJ, et al
    Risk of Guillain-Barre Syndrome Following COVID-19 Vaccines: A Nationwide Self-controlled Case Series Study.
    Neurology. 2023 Oct 3:10.1212/WNL.0000000000207847.
    PubMed     Abstract available
    
    
    September 2023
75. COBO-CALVO A, Tur C, Otero-Romero S, Carbonell-Mirabent P, et al
    Association of Very Early Treatment Initiation With the Risk of Long-term Disability in Patients With a First Demyelinating Event.
    Neurology. 2023;101:e1280-e1292.
    PubMed     Abstract available
    
    
    
76. PALLADINO R, Strijbis EM
    How Far Are We in Translating the Multiple Sclerosis Prodromes in Clinical Practice?
    Neurology. 2023 Sep 25:10.1212/WNL.0000000000207989.
    PubMed    
    
    
    
77. CHERTCOFF AS, Yusuf F, Zhu F, Evans C, et al
    Psychiatric Comorbidity During the Prodromal Period in Patients With Multiple Sclerosis.
    Neurology. 2023 Sep 25:10.1212/WNL.0000000000207843.
    PubMed     Abstract available
    
    
    
78. HUPPKE BM, Reinert M, Hummel-Abmeier H, Stark W, et al
    Pretreatment Neurofilament Light Chain Serum Levels, Early Disease Severity, and Treatment Response in Pediatric Multiple Sclerosis.
    Neurology. 2023 Sep 25:10.1212/WNL.0000000000207791.
    PubMed     Abstract available
    
    
    
79. ALMRAMHI MM, Finan C, Storm CS, Schmidt AF, et al
    Exploring the Role of Plasma Lipids and Statins Interventions on Multiple Sclerosis Risk and Severity: A Mendelian Randomization Study.
    Neurology. 2023 Sep 1:10.1212/WNL.0000000000207777.
    PubMed     Abstract available
    
    
    
80. BUYUKKURT A, Harroud A
    The Potential to Inform Statin Use in Multiple Sclerosis Through Human Genetics [re: WNL-2023-000524].
    Neurology. 2023 Sep 1:10.1212/WNL.0000000000207773.
    PubMed    
    
    
    August 2023
81. JACOBS BC
    [Correction] CSF Findings in Relation to Clinical Characteristics, Subtype, and Disease Course in Patients With Guillain-Barre Syndrome.
    Neurology. 2023 Aug 29:10.1212/WNL.0000000000207874.
    PubMed    
    
    
    
82. FANG CEH, Bokre D, Wong SH
    Clinical Characteristics Associated With Secondary Generalization in Ocular Myasthenia Gravis Patients: A Systematic Review and Meta-analysis.
    Neurology. 2023 Aug 29:10.1212/WNL.0000000000207642.
    PubMed     Abstract available
    
    
    
83. BSTEH G, Hegen H, Altmann P, Auer M, et al
    Diagnostic Performance of Adding the Optic Nerve Region Assessed by Optical Coherence Tomography to the Diagnostic Criteria for Multiple Sclerosis.
    Neurology. 2023;101:e784-e793.
    PubMed     Abstract available
    
    
    
84. GRAVES JS
    Cell Specific Aging in Multiple Sclerosis.
    Neurology. 2023 Aug 4:10.1212/WNL.0000000000207679.
    PubMed    
    
    
    
85. MALTBY V, Xavier A, Ewing E, Campagna MP, et al
    Evaluation of Cell-Specific Epigenetic Age Acceleration in People With Multiple Sclerosis.
    Neurology. 2023 Aug 4:10.1212/WNL.0000000000207489.
    PubMed     Abstract available
    
    
    July 2023
86. BRAYO P, Serrano E, Thakkar RS, Osborne B, et al
    Pearls & Oy-sters: Syndrome of Inappropriate Antidiuretic Hormone Secretion Presenting as Neuromyelitis Optica Spectrum Disorder Flare.
    Neurology. 2023;101:e455-e458.
    PubMed     Abstract available
    
    
    
87. HACOHEN Y, Tur C
    Treatment De-escalation in AQP4-Ab Neuromyelitis Optica Spectrum Disorder.
    Neurology. 2023;101:153-154.
    PubMed    
    
    
    
88. DEMUTH S, Collongues N, Audoin B, Ayrignac X, et al
    Rituximab De-escalation in Patients With Neuromyelitis Optica Spectrum Disorder.
    Neurology. 2023;101:e438-e450.
    PubMed     Abstract available
    
    
    
89. FADDA G, Cardenas de la Parra A, O'Mahony J, Waters P, et al
    Deviation From Normative Whole Brain and Deep Gray Matter Growth in Children With MOGAD, MS, and Monophasic Seronegative Demyelination.
    Neurology. 2023;101:e425-e437.
    PubMed     Abstract available
    
    
    
90. QUINN C, Moulton K, Farwell M, Le W, et al
    Imaging With PET/CT of Diffuse CD8 T Cell Infiltration of Skeletal Muscle in Patients with Inclusion Body Myositis.
    Neurology. 2023 Jul 24:10.1212/WNL.0000000000207596.
    PubMed     Abstract available
    
    
    
91. COUSTAL C, Goulabchand R, Labauge P, Guilpain P, et al
    Clinical, Radiologic, and Immunologic Features of Patients With CTLA4 Deficiency With Neurologic Involvement.
    Neurology. 2023 Jul 24:10.1212/WNL.0000000000207609.
    PubMed     Abstract available
    
    
    
92. SCHWEITZER F, Laurent S, Cortese I, Fink GR, et al
    Progressive Multifocal Leukoencephalopathy: Pathogenesis, Diagnostic Tools, and Potential Biomarkers of Response to Therapy.
    Neurology. 2023 Jul 24:10.1212/WNL.0000000000207622.
    PubMed     Abstract available
    
    
    
93. LONGBRAKE E, Kalincik T
    Early Treatment for Multiple Sclerosis: Time Is Brain.
    Neurology. 2023 Jul 19:10.1212/WNL.0000000000207754.
    PubMed    
    
    
    
94. EHRHARDT H, Lambe J, Moussa H, Vasileiou ES, et al
    Effects of Ibudilast on Retinal Atrophy in Progressive Multiple Sclerosis Subtypes: Post-Hoc Analyses of the SPRINT-MS Trial.
    Neurology. 2023 Jul 17:10.1212/WNL.0000000000207551.
    PubMed     Abstract available
    
    
    
95. HOSHINA Y, Wright MA, Warner JE, Richards T, et al
    Pearls & Oy-sters: ATX-FGF14 Mimicking Autoimmune Pathology.
    Neurology. 2023 Jul 17:10.1212/WNL.0000000000207590.
    PubMed     Abstract available
    
    
    
96. BENNETT JL
    Sprinting to the Finish: Optical Coherence Tomography, Retinal Atrophy, and Neurodegeneration in Progressive Multiple Sclerosis.
    Neurology. 2023 Jul 17:10.1212/WNL.0000000000207607.
    PubMed    
    
    
    
97. LEVIT E, Leon J, Lincoln MR
    Pearls & Oy-sters: Homozygous Complement Factor I Deficiency Presenting as Fulminant Relapsing Complement-Mediated CNS Vasculitis.
    Neurology. 2023;101:e220-e223.
    PubMed     Abstract available
    
    
    
98. JAIN A, Arena VP, Steigerwald C, Borja MJ, et al
    Pearls and Oy-sters: CSF1R-Related Leukoencephalopathy With Spinal Cord Lesions Mimicking Multiple Sclerosis.
    Neurology. 2023 Jul 5:10.1212/WNL.0000000000207502.
    PubMed     Abstract available
    
    
    
99. BAARS AE, Van Doorn PA, Jacobs BC, Kuitwaard K, et al
    Author Response: SARS-CoV-2 Vaccination Safety in Guillain-Barre Syndrome, Chronic Inflammatory Demyelinating Polyneuropathy, and Multifocal Motor Neuropathy.
    Neurology. 2023;101:51.
    PubMed    
    
    
    
100. HARTH CE
     Reader Response: SARS-CoV-2 Vaccination Safety in Guillain-Barre Syndrome, Chronic Inflammatory Demyelinating Polyneuropathy, and Multifocal Motor Neuropathy.
     Neurology. 2023;101:50-51.
     PubMed    
     
     
     
101. TOOSY AT, Vidal-Jordana A
     Is the Optic Nerve Overdue as a Criterion to Support the Diagnosis of Multiple Sclerosis?
     Neurology. 2023 Jul 3:10.1212/WNL.0000000000207625.
     PubMed    
     
     
     June 2023
102. KOCH-HENRIKSEN N
     Worldwide Disparity in the Effectiveness of the Diagnostic Process in Multiple Sclerosis.
     Neurology. 2023 Jun 30:10.1212/WNL.0000000000207530.
     PubMed    
     
     
     
103. SOLOMON AJ, Marrie RA, Viswanathan S, Correale J, et al
     Global Barriers to the Diagnosis of Multiple Sclerosis: Data From the Multiple Sclerosis International Federation Atlas of MS, Third Edition.
     Neurology. 2023 Jun 15:10.1212/WNL.0000000000207481.
     PubMed     Abstract available
     
     
     
104. ROTSTEIN D, Schneider R
     A Birth Year Cohort and What It Can Reveal About Lipid Mediators as Putative Biomarkers of Progression in Multiple Sclerosis.
     Neurology. 2023 Jun 8:10.1212/WNL.0000000000207605.
     PubMed    
     
     
     
105. BROOS JY, Loonstra FC, de Ruiter LRJ, Gouda MMTEE, et al
     Association of Arachidonic Acid-Derived Lipid Mediators With Disease Severity in Patients With Relapsing and Progressive Multiple Sclerosis.
     Neurology. 2023 Jun 8:10.1212/WNL.0000000000207459.
     PubMed     Abstract available
     
     
     
106. KOWALEC K, Fitzgerald KC, Salter A, Dolovich C, et al
     Polygenicity of Comorbid Depression in Multiple Sclerosis.
     Neurology. 2023 Jun 8:10.1212/WNL.0000000000207457.
     PubMed     Abstract available
     
     
     May 2023
107. SUN H, Zhang S, Yu T, Zhou D, et al
     Teaching NeuroImage: Primary CNS Vasculitis Mimicking Intracranial Tumor.
     Neurology. 2023;100:1072-1073.
     PubMed    
     
     
     
108. BRENNER J, Mariotto S, Bastiaansen AEM, Paunovic M, et al
     Predictive Value of Serum Neurofilament Light Chain Levels in Anti-NMDA Receptor Encephalitis.
     Neurology. 2023;100:e2204-e2213.
     PubMed     Abstract available
     
     
     
109. KUNCHOK A, Dalmau J
     Can Neurofilament Light Chain Be Utilized as a Biomarker of Disease Severity, Activity, and Outcomes in Anti-NMDA Receptor Encephalitis?
     Neurology. 2023;100:991-992.
     PubMed    
     
     
     
110. SCHEEL M, Pruss H, Finke C
     Reader Response: Teaching NeuroImage: Atypical Unilateral Cortical Ribboning in Anti-NMDA Receptor Encephalitis.
     Neurology. 2023;100:887.
     PubMed    
     
     
     
111. GANESH A, Galetta S
     Editors' Note: Teaching NeuroImage: Atypical Unilateral Cortical Ribboning in Anti-NMDA Receptor Encephalitis.
     Neurology. 2023;100:886.
     PubMed    
     
     
     
112. BUDHRAM A, Mirian A, Sharma M
     Reader Response: Teaching NeuroImage: Atypical Unilateral Cortical Ribboning in Anti-NMDA Receptor Encephalitis.
     Neurology. 2023;100:886-887.
     PubMed    
     
     
     April 2023
113. LUSK JB, Hoffman MN, Clark AG, Bae J, et al
     Association Between Neighborhood Socioeconomic Status and 30-Day Mortality and Readmission for Patients With Common Neurologic Conditions.
     Neurology. 2023;100:e1776-e1786.
     PubMed     Abstract available
     
     
     
114. 
     Randomized Double-Blind Placebo-Controlled Trial of the Corticosteroid-Sparing Effects of Immunoglobulin in Myasthenia Gravis.
     Neurology. 2023 Apr 25:10.1212/WNL.0000000000207433.
     PubMed    
     
     
     
115. AL-HAKEM H, Doets AY, Stino AM, Zivkovic SA, et al
     Cerebrospinal Fluid Findings in Relation to Clinical Characteristics, Subtype, and Disease Course in Patients With Guillain-Barre Syndrome.
     Neurology. 2023 Apr 19:10.1212/WNL.0000000000207282.
     PubMed     Abstract available
     
     
     
116. SEJVAR J
     Cerebrospinal Fluid In Guillain-Barre Syndrome: It's a Matter of Timing.
     Neurology. 2023 Apr 19:10.1212/WNL.0000000000207203.
     PubMed    
     
     
     
117. GUPTILL JT, Benatar M, Granit V, Habib AA, et al
     Addressing Outcome Measure Variability in Myasthenia Gravis Clinical Trials.
     Neurology. 2023 Apr 19:10.1212/WNL.0000000000207278.
     PubMed     Abstract available
     
     
     
118. LEAVITT VM
     The Mismeasure of Change: Better Cognitive Measurement Instruments are Urgently Needed for Multiple Sclerosis Research.
     Neurology. 2023 Apr 18:10.1212/WNL.0000000000207431.
     PubMed    
     
     
     
119. CASTROGIOVANNI N, Mostert J, Repovic P, Bowen JD, et al
     Longitudinal Changes in Cognitive Test Scores in Patients With Relapsing Remitting Multiple Sclerosis: An Analysis of the DECIDE Dataset.
     Neurology. 2023 Apr 18:10.1212/WNL.0000000000207301.
     PubMed     Abstract available
     
     
     March 2023
120. KIM HJ, Palace J
     Should We test for IgG Antibodies Against MOG in Both Serum and CSF in Patients With Suspected MOGAD?
     Neurology. 2023;100:497-498.
     PubMed    
     
     
     
121. CARTA S, Cobo Calvo A, Armangue T, Saiz A, et al
     Significance of Myelin Oligodendrocyte Glycoprotein Antibodies in CSF: A Retrospective Multicenter Study.
     Neurology. 2023;100:e1095-e1108.
     PubMed     Abstract available
     
     
     February 2023
122. PIZZOLATO UMETON R, Waltz M, Aaen GS, Benson L, et al
     Therapeutic Response in Pediatric Neuromyelitis Optica Spectrum Disorder.
     Neurology. 2023;100:e985-e994.
     PubMed     Abstract available
     
     
     
123. LALLA R, Narasimhan R, Abdalkader M, Virmani D, et al
     Teaching NeuroImage: Imaging and Pathologic Findings in SARS-CoV-2-Related Acute Demyelinating Encephalomyelitis.
     Neurology. 2023 Feb 16:10.1212/WNL.0000000000207095.
     PubMed    
     
     
     
124. LEWIS A, Galetta S
     Editors' Note: Teaching Video NeuroImage: Bilateral Hemifacial Spasm in Giant Cell Arteritis.
     Neurology. 2023;100:310-311.
     PubMed    
     
     
     
125. LEWIS A, Galetta S
     Editors' Note: Frequency of Asymptomatic Optic Nerve Enhancement in a Large Retrospective Cohort of Patients With Aquaporin-4+ NMOSD.
     Neurology. 2023;100:309.
     PubMed    
     
     
     
126. CORNBLATH W, Eggenberger E
     Reader Response: Teaching Video NeuroImage: Bilateral Hemifacial Spasm in Giant Cell Arteritis.
     Neurology. 2023;100:311.
     PubMed    
     
     
     
127. SECHI E, Defazio G, Erre GL, Solla P, et al
     Author Response: Teaching Video NeuroImage: Bilateral Hemifacial Spasm in Giant Cell Arteritis.
     Neurology. 2023;100:311-312.
     PubMed    
     
     
     
128. CAO S, Zhu Y, Xue Q, Xia M, et al
     Reader Response: Frequency of Asymptomatic Optic Nerve Enhancement in a Large Retrospective Cohort of Patients With Aquaporin-4+ NMOSD.
     Neurology. 2023;100:309-310.
     PubMed    
     
     
     
129. CHEN J, Shah S
     Author Response: Frequency of Asymptomatic Optic Nerve Enhancement in a Large Retrospective Cohort of Patients With Aquaporin-4+ NMOSD.
     Neurology. 2023;100:310.
     PubMed    
     
     
     January 2023
130. LEONHARD SE, van der Eijk AA, Willison HJ, Jacobs BC, et al
     Author Response: An International Perspective on Preceding Infections in Guillain-Barre Syndrome: The IGOS-1000 Cohort.
     Neurology. 2023;100:264.
     PubMed    
     
     
     
131. DEBNATH M, Nagappa M
     Reader Response: An International Perspective on Preceding Infections in Guillain-Barre Syndrome: The IGOS-1000 Cohort.
     Neurology. 2023;100:263-264.
     PubMed    
     
     
     
132. GANESH A, Galetta S
     Editors' Note: An International Perspective on Preceding Infections in Guillain-Barre Syndrome: The IGOS-1000 Cohort.
     Neurology. 2023;100:263.
     PubMed    
     
     
     
133. PATIL SA, Grossman S, Kenney R, Balcer LJ, et al
     Where's the Vision? The Importance of Visual Outcomes in Neurologic Disorders: The 2021 H. Houston Merritt Lecture.
     Neurology. 2023;100:244-253.
     PubMed     Abstract available
     
     
     
134. 
     Pathologic Features of Anti-Mi-2 Dermatomyositis.
     Neurology. 2023 Jan 24:10.1212/WNL.0000000000201611.
     PubMed    
     
     
     
135. CACCIAGUERRA L, Morris P, Tobin WO, Chen JJ, et al
     Tumefactive Demyelination in MOG Ab-Associated Disease, Multiple Sclerosis, and AQP-4-IgG-Positive Neuromyelitis Optica Spectrum Disorder.
     Neurology. 2023 Jan 23:10.1212/WNL.0000000000206820.
     PubMed     Abstract available
     
     
     
136. HORTON MK, Robinson SC, Shao X, Quach H, et al
     A Cross-Trait, Mendelian Randomization Study to Investigate Whether Migraine Is a Risk Factor for Multiple Sclerosis.
     Neurology. 2023 Jan 11:10.1212/WNL.0000000000206791.
     PubMed     Abstract available
     
     
     December 2022
137. DONCEL-MORIANO CUBERO A, Espigol G, Renu A
     Teaching NeuroImage: Bilateral Internal Carotid Artery Stenosis Due to Aggressive Giant Cell Arteritis.
     Neurology. 2022 Dec 23:10.1212/WNL.0000000000206823.
     PubMed    
     
     
     
138. BORDEA E, Hunter RM
     Excess Treatment Costs of Multiple Sclerosis: What Can We Learn From Longitudinal Population-Based Data?
     Neurology. 2022 Dec 23:10.1212/WNL.0000000000206804.
     PubMed    
     
     
     
139. GAVOILLE A, Rollot F, Casey R, Debouverie M, et al
     Investigating the Long-term Effect of Pregnancy on the Course of Multiple Sclerosis Using Causal Inference.
     Neurology. 2022 Dec 23:10.1212/WNL.0000000000206774.
     PubMed     Abstract available
     
     
     
140. BERGSLAND N, Dwyer MG, Jakimovski D, Tavazzi E, et al
     Association of Choroid Plexus Inflammation on MRI With Clinical Disability Progression Over 5 Years in Patients With Multiple Sclerosis.
     Neurology. 2022 Dec 21:10.1212/WNL.0000000000201608.
     PubMed     Abstract available
     
     
     
141. BOFFA G, Signori A, Massacesi L, Mariottini A, et al
     Hematopoietic Stem Cell Transplantation in People With Active Secondary Progressive Multiple Sclerosis.
     Neurology. 2022 Dec 21:10.1212/WNL.0000000000206750.
     PubMed     Abstract available
     
     
     
142. MULLER J, Noteboom S, Granziera C, Schoonheim MM, et al
     Understanding the Role of the Choroid Plexus in Multiple Sclerosis as an MRI Biomarker of Disease Activity.
     Neurology. 2022 Dec 21:10.1212/WNL.0000000000206806.
     PubMed    
     
     
     
143. MULLER-JENSEN L, Kriedemann H, Anvari K, Huehnchen P, et al
     Complicated Monkeypox Infection in a Patient With Multiple Sclerosis and Fingolimod Treatment.
     Neurology. 2022 Dec 20:10.1212/WNL.0000000000206743.
     PubMed    
     
     
     November 2022
144. KHAKBAN A, Llorian ER, Michaux KD, Patten SB, et al
     Direct Health Care Costs Associated With Multiple Sclerosis: A Population-Based Cohort Study From 2001 to 2020 in British Columbia, Canada.
     Neurology. 2022 Nov 30:10.1212/WNL.0000000000201645.
     PubMed     Abstract available
     
     
     
145. BARRERAS P, Vasileiou ES, Filippatou AG, Fitzgerald KC, et al
     Long-term Effectiveness and Safety of Rituximab in Neuromyelitis Optica Spectrum Disorder and MOG Antibody Disease.
     Neurology. 2022;99:e2504-e2516.
     PubMed     Abstract available
     
     
     
146. ZIEMSSEN T
     Reader Response: NfL as Analogue of C-Reactive Protein in Neurologic Diseases: Instructions for Use.
     Neurology. 2022;99:868.
     PubMed    
     
     
     
147. PARNETTI L, Gaetani L
     Author Response: NfL as Analogue of C-Reactive Protein in Neurologic Diseases: Instructions for Use.
     Neurology. 2022;99:869.
     PubMed    
     
     
     
148. DEERHAKE ME, Giarraputo J, Gupta M, Eckstein C, et al
     Journal Club: Neurofilament Light Chain Levels in Anti-NMDAR Encephalitis and Primary Psychiatric Psychosis.
     Neurology. 2022;99:854-857.
     PubMed    
     
     
     
149. LEWIS A, Galetta S
     Editors' Note: The Economic Burden of Multiple Sclerosis in the United States: Estimate of Direct and Indirect Costs.
     Neurology. 2022;99:818.
     PubMed    
     
     
     
150. BEBO BF
     Author Response: The Economic Burden of Multiple Sclerosis in the United States: Estimate of Direct and Indirect Costs.
     Neurology. 2022;99:819.
     PubMed    
     
     
     
151. VARGAS WS
     Reader Response: The Economic Burden of Multiple Sclerosis in the United States: Estimate of Direct and Indirect Costs.
     Neurology. 2022;99:818-819.
     PubMed    
     
     
     October 2022
152. LI L, Avina-Zubieta JA, Bernstein CN, Kaplan GG, et al
     Risk of Multiple Sclerosis Among Users of Antitumor Necrosis Factor Alpha in Four Canadian Provinces: A Population-Based Study.
     Neurology. 2022 Oct 28. pii: WNL.0000000000201472.
     PubMed     Abstract available
     
     
     
153. 
     Initial high-efficacy disease-modifying therapy in multiple sclerosis: A nationwide cohort study.
     Neurology. 2022 Oct 28. pii: WNL.0000000000201391.
     PubMed    
     
     
     
154. STRIJBIS EMM, Koch MW
     TNF Alfa Blockers and the Risk of Multiple Sclerosis.
     Neurology. 2022 Oct 28. pii: WNL.0000000000201629.
     PubMed    
     
     
     
155. DOBSON R, Bove R
     In Vitro Fertilization and Multiple Sclerosis: Evolving Treatments and Reducing Relapse Risk.
     Neurology. 2022;99:737-738.
     PubMed    
     
     
     
156. BRIL V, Szczudlik A, Vaitkus A, Rozsa C, et al
     A Randomized, Double-Blind, Placebo-Controlled Trial of the Corticosteroid-Sparing Effects of Immunoglobulin in Myasthenia Gravis.
     Neurology. 2022 Oct 21. pii: WNL.0000000000201501.
     PubMed     Abstract available
     
     
     
157. DUBESSY AL, Stankoff B, Arnulf I
     Author Response: Association of Central Hypersomnia and Fatigue in Patients With Multiple Sclerosis: A Polysomnographic Study.
     Neurology. 2022;99:727.
     PubMed    
     
     
     
158. SIEGLER JE, Galetta S
     Editors' Note: Association of Central Hypersomnia and Fatigue in Patients With Multiple Sclerosis: A Polysomnographic Study.
     Neurology. 2022;99:726.
     PubMed    
     
     
     
159. SPARASCI D, Zecca C, Gobbi C, Manconi M, et al
     Reader Response: Association of Central Hypersomnia and Fatigue in Patients With Multiple Sclerosis: A Polysomnographic Study.
     Neurology. 2022;99:726-727.
     PubMed    
     
     
     
160. SNETSELAAR L, Cheek JJ, Fox SS, Healy HS, et al
     Efficacy of Diet on Fatigue and Quality of Life in Multiple Sclerosis: A Systematic Review and Network Meta-analysis of Randomized Trials.
     Neurology. 2022 Oct 18. pii: WNL.0000000000201371.
     PubMed     Abstract available
     
     
     
161. SPAIN R, Piccio L, Langer-Gould AM
     The Role of Diet in Multiple Sclerosis: Food for Thought.
     Neurology. 2022 Oct 18. pii: WNL.0000000000201565.
     PubMed    
     
     
     
162. MURPHY OC, Calabresi PA, Gold DR
     Teaching Video NeuroImage: Dramatic Response to Topiramate in Acquired Pendular Nystagmus From Multiple Sclerosis.
     Neurology. 2022 Oct 11. pii: WNL.0000000000201452.
     PubMed    
     
     
     
163. GANESH A, Galetta S
     Editors' Note: Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials.
     Neurology. 2022;99:630.
     PubMed    
     
     
     
164. BARRO C
     Reader Response: Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials.
     Neurology. 2022;99:630-631.
     PubMed    
     
     
     
165. LEPPERT D, Kropshofer H, Haring D, Dahlke F, et al
     Author Response: Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials.
     Neurology. 2022;99:631.
     PubMed    
     
     
     
166. CORTESE R, Carrasco FP, Tur C, Bianchi A, et al
     Differentiating Multiple Sclerosis From AQP4-Neuromyelitis Optica Spectrum Disorder and MOG-Antibody Disease With Imaging.
     Neurology. 2022 Oct 3. pii: WNL.0000000000201465.
     PubMed     Abstract available
     
     
     September 2022
167. B SYC-MAZUREK S, Chen JJ, Morris P, Sechi E, et al
     Frequency of New or Enlarging Lesions on MRI Outside of Clinical Attacks in Patients With MOG-Antibody-Associated Disease.
     Neurology. 2022 Sep 29. pii: WNL.0000000000201263.
     PubMed     Abstract available
     
     
     
168. BAARS AE, Kuitwaard K, de Koning LC, Luijten LWG, et al
     SARS-CoV-2 Vaccination Safety in Guillain-Barre Syndrome, Chronic Inflammatory Demyelinating Polyneuropathy, and Multifocal Motor Neuropath.
     Neurology. 2022 Sep 20. pii: WNL.0000000000201376.
     PubMed     Abstract available
     
     
     
169. ALLEN JA
     SARS-CoV-2 Vaccination and Autoimmune Neuropathies: Rebalancing the Risk.
     Neurology. 2022 Sep 20. pii: WNL.0000000000201366.
     PubMed    
     
     
     
170. COTE-OROZCO JE, Velez-Tirado N
     Teaching NeuroImage: Hypothalamic Involvement in Neuromyelitis Optica Spectrum Disorder in a Child.
     Neurology. 2022;99:535-536.
     PubMed    
     
     
     
171. GANESH A, Galetta S
     Editors' Note: Neurofilament Light Chain Levels in Anti-NMDAR Encephalitis and Primary Psychiatric Psychosis.
     Neurology. 2022;99:489.
     PubMed    
     
     
     
172. VALE S
     Reader Response: Neurofilament Light Chain Levels in Anti-NMDAR Encephalitis and Primary Psychiatric Psychosis.
     Neurology. 2022;99:491.
     PubMed    
     
     
     
173. GUASP M, Dalmau J
     Author Response: Neurofilament Light Chain Levels in Anti-NMDAR Encephalitis and Primary Psychiatric Psychosis.
     Neurology. 2022;99:490.
     PubMed    
     
     
     
174. JEANTIN L, Plu I, Amador MDM, Maillart E, et al
     Pearls & Oy-sters: Spinal Cord Candidiasis Linked to CARD9 Deficiency Masquerading as a Longitudinally Extensive Transverse Myelitis.
     Neurology. 2022;99:475-479.
     PubMed     Abstract available
     
     
     
175. CAROTENUTO A, Valsasina P, Schoonheim MM, Geurts JJ, et al
     Investigating Functional Network Abnormalities and Associations With Disability in Multiple Sclerosis.
     Neurology. 2022 Sep 12. pii: WNL.0000000000201264.
     PubMed     Abstract available
     
     
     August 2022
176. BASTERRA PP, Nombela F, Iriarte P, Del Rincon CR, et al
     Proprioceptive Stimuli as a New Type of Trigger for Epilepsy in Stiff Person Syndrome.
     Neurology. 2022 Aug 31. pii: WNL.0000000000201196.
     PubMed    
     
     
     
177. CORDANO C, Nourbakhsh B, Yiu HH, Papinutto N, et al
     Differences in Age-Related Retinal and Cortical Atrophy Rates in Multiple Sclerosis.
     Neurology. 2022 Aug 29. pii: WNL.0000000000200977.
     PubMed     Abstract available
     
     
     
178. VILLOSLADA P, Llufriu S
     Preventing Neurodegeneration in Multiple Sclerosis Is Required From the Earliest Stages of the Disease.
     Neurology. 2022 Aug 29. pii: WNL.0000000000201223.
     PubMed    
     
     
     
179. HWANG S, Garcia-Dominguez MA, Fitzgerald KC, Saylor DR, et al
     Association of Multiple Sclerosis Prevalence With Sociodemographic, Health Systems, and Lifestyle Factors on a National and Regional Level.
     Neurology. 2022 Aug 24. pii: WNL.0000000000200962.
     PubMed     Abstract available
     
     
     
180. LOPEZ-JIMENEZ A, Gutierrez-Gutierrez G, Guerra-Hiraldo JD, Kurtis MM, et al
     Teaching Video NeuroImage: Hung-Up Reflex in Stiff Limb Syndrome.
     Neurology. 2022;99:356.
     PubMed    
     
     
     
181. SHAH SS, Morris P, Buciuc M, Tajfirouz D, et al
     Frequency of Asymptomatic Optic Nerve Enhancement in a Large Retrospective Cohort of Patients With Aquaporin-4+ NMOSD.
     Neurology. 2022;99:e851-e857.
     PubMed     Abstract available
     
     
     
182. BRENTON JN, Florenzo B, Koshiya H, Min S, et al
     Six-Minute Walk as a Measure of Walking Capacity and Endurance in Patients With Pediatric-Onset Multiple Sclerosis.
     Neurology. 2022 Aug 19. pii: WNL.0000000000201098.
     PubMed     Abstract available
     
     
     
183. LEONHARD SE, van der Eijk AA, Andersen H, Antonini G, et al
     An International Perspective on Preceding Infections in Guillain-Barre Syndrome: The IGOS-1000 Cohort.
     Neurology. 2022 Aug 18. pii: WNL.0000000000200885.
     PubMed     Abstract available
     
     
     
184. ROOS I, Malpas C, Leray E, Casey R, et al
     Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis.
     Neurology. 2022 Aug 17. pii: WNL.0000000000201029.
     PubMed     Abstract available
     
     
     
185. MCLAREN JR, Mitchell MK, Al-Maadid FM, Staley KJ, et al
     Clinical Reasoning: An 8-Year-Old With Acute Onset Ataxia.
     Neurology. 2022;99:305-310.
     PubMed     Abstract available
     
     
     
186. DOBSON R, Bove R
     IVF and Multiple Sclerosis: Evolving Treatments and Reducing Relapse Risk.
     Neurology. 2022 Aug 11. pii: WNL.0000000000201242.
     PubMed    
     
     
     
187. MAINGUY M, Tillaut H, Degremont A, Le Page E, et al
     Assessing the Risk of Relapse Requiring Corticosteroids After In Vitro Fertilization in Women With Multiple Sclerosis.
     Neurology. 2022 Aug 11. pii: WNL.0000000000201027.
     PubMed     Abstract available
     
     
     
188. O'MAHONY J, Salter A, Ciftci B, Fox RJ, et al
     Physical and Mental Health-Related Quality of Life Trajectories Among People With Multiple Sclerosis.
     Neurology. 2022 Aug 10. pii: WNL.0000000000200931.
     PubMed     Abstract available
     
     
     
189. SECHI E, Gallus E, Solla P, Puggioni D, et al
     Teaching Video NeuroImage: Bilateral Hemifacial Spasm in Giant Cell Arteritis.
     Neurology. 2022;99:256-257.
     PubMed    
     
     
     
190. PIAZZA F, Caminiti SP, Zedde M, Presotto L, et al
     Association of Microglial Activation With Spontaneous ARIA-E and Cerebrospinal Fluid Levels of Anti-A Autoantibodies.
     Neurology. 2022 Aug 8. pii: WNL.0000000000200892.
     PubMed     Abstract available
     
     
     
191. BSTEH G, Krajnc N, Riedl K, Altmann P, et al
     Retinal Layer Thinning After Optic Neuritis is Associated With Future Relapse Remission in Relapsing Multiple Sclerosis.
     Neurology. 2022 Aug 2. pii: WNL.0000000000200970.
     PubMed     Abstract available
     
     
     July 2022
192. KUANG SY, Li Y, Yang SL, Han X, et al
     Child Neurology: Aicardi-Goutieres Syndrome Presenting as Recurrent Ischemic Stroke.
     Neurology. 2022 Jul 8. pii: WNL.0000000000200952.
     PubMed     Abstract available
     
     
     June 2022
193. KENNEY RC, Liu M, Hasanaj L, Joseph B, et al
     The Role of OCT Criteria and Machine Learning in Multiple Sclerosis and Optic Neuritis Diagnosis.
     Neurology. 2022 Jun 28. pii: WNL.0000000000200883.
     PubMed     Abstract available
     
     
     
194. TOOSY AT, Eshaghi A
     Machine Learning Utility for Optical Coherence Tomography in Multiple Sclerosis: Is the Future Now?
     Neurology. 2022 Jun 28. pii: WNL.0000000000200862.
     PubMed    
     
     
     
195. FREEDMAN MS, Pozzilli C, Havrdova EK, Lemle A, et al
     Long-term Treatment With Ponesimod in Relapsing-Remitting Multiple Sclerosis: Results from Randomized Phase 2b Core and Extension Studies.
     Neurology. 2022 Jun 6. pii: WNL.0000000000200606.
     PubMed     Abstract available
     
     
     May 2022
196. SOTIRCHOS ES, Vasileiou ES, Filippatou AG, Fitzgerald KC, et al
     Association of Serum Neurofilament Light Chain With Inner Retinal Layer Thinning in Multiple Sclerosis.
     Neurology. 2022 May 26. pii: WNL.0000000000200778.
     PubMed     Abstract available
     
     
     
197. GRAVES J
     Identifying Multiple Sclerosis Activity: Do the Eyes Have It?
     Neurology. 2022 May 26. pii: WNL.0000000000200903.
     PubMed    
     
     
     
198. YANG JH, Graves JS
     Cancer Screening in Patients With Multiple Sclerosis: Are We Doing Enough?
     Neurology. 2022;98:737-738.
     PubMed    
     
     
     
199. LANGER-GOULD AM, Gonzales EG, Smith JB, Li BH, et al
     Racial and Ethnic Disparities in Multiple Sclerosis Prevalence.
     Neurology. 2022;98:e1818-e1827.
     PubMed     Abstract available
     
     
     
200. GROOME PA, Webber C, Maxwell CJ, McClintock C, et al
     Multiple Sclerosis and the Cancer Diagnosis: Diagnostic Route, Cancer Stage, and the Diagnostic Interval in Breast and Colorectal Cancer.
     Neurology. 2022;98:e1798-e1809.
     PubMed     Abstract available
     
     
     April 2022
201. WU Q, Zhao CW, Dai S
     Teaching Video NeuroImage: Generalized Reflex Myoclonus in Autoimmune Hepatitis-Primary Biliary Cholangitis Overlap Syndrome.
     Neurology. 2022 Apr 29. pii: WNL.0000000000200733.
     PubMed    
     
     
     
202. YANG JH, Graves JS
     Cancer Screening in Patients With Multiple Sclerosis: Are We Doing Enough?
     Neurology. 2022 Apr 28. pii: WNL.0000000000200366.
     PubMed    
     
     
     
203. HAMILTON R, Ciccarelli O
     Multiple Sclerosis Incidence in Black Patients: It's Time to Do Away With a Racial Medical Myth.
     Neurology. 2022 Apr 28. pii: WNL.0000000000200309.
     PubMed    
     
     
     
204. LANGER-GOULD AM, Gonzales EG, Smith JB, Li BH, et al
     Racial and Ethnic Disparities in Multiple Sclerosis Prevalence.
     Neurology. 2022 Apr 28. pii: WNL.0000000000200151.
     PubMed     Abstract available
     
     
     
205. GROOME PA, Webber C, Maxwell CJ, McClintock C, et al
     Multiple Sclerosis and the Cancer Diagnosis: Diagnostic Route, Cancer Stage, and the Diagnostic Interval in Breast and Colorectal Cancer.
     Neurology. 2022 Apr 28. pii: WNL.0000000000200163.
     PubMed     Abstract available
     
     
     
206. ROTSTEIN D, Solomon JM, Sormani MP, Montalban X, et al
     Association of No Evidence of Disease Activity With No Long-term Disability Progression in Multiple Sclerosis: A Systematic Review and Meta-analysis.
     Neurology. 2022 Apr 26. pii: WNL.0000000000200549.
     PubMed     Abstract available
     
     
     
207. OKAI AF, Howard AM, Williams MJ, Brink JD, et al
     Advancing Care and Outcomes for African American Patients With Multiple Sclerosis.
     Neurology. 2022 Apr 25. pii: WNL.0000000000200791.
     PubMed     Abstract available
     
     
     
208. PORTACCIO E, Bellinvia A, Razzolini L, Pasto L, et al
     Long-term Cognitive Outcomes and Socioprofessional Attainment in People With Multiple Sclerosis With Childhood Onset.
     Neurology. 2022;98:e1626-e1636.
     PubMed     Abstract available
     
     
     
209. SWART G, Balgobind S, Chan C, Fulham M, et al
     Spinal Cord Presentation of Biopsy-Proven PET-Positive Giant Cell Arteritis.
     Neurology. 2022 Apr 15. pii: WNL.0000000000200749.
     PubMed     Abstract available
     
     
     
210. BEBO B, Cintina I, LaRocca N, Ritter L, et al
     Economic Burden of Multiple Sclerosis in the United States: Estimate of Direct and Indirect Costs.
     Neurology. 2022 Apr 13. pii: WNL.0000000000200150.
     PubMed     Abstract available
     
     
     
211. OSTKAMP P, Schwab N
     Effects of Latitude and Sunlight on Multiple Sclerosis Severity: Two Peas in a Pod?
     Neurology. 2022 Apr 11. pii: WNL.0000000000200105.
     PubMed    
     
     
     
212. VITKOVA M, Diouf I, Malpas C, Horakova D, et al
     Association of Latitude and Exposure to Ultraviolet B Radiation With Severity of Multiple Sclerosis: An International Registry Study.
     Neurology. 2022 Apr 11. pii: WNL.0000000000200545.
     PubMed     Abstract available
     
     
     
213. GUASP M, Martin-Aguilar L, Sabater L, Bioque M, et al
     Neurofilament Light Chain Levels in Anti-NMDAR Encephalitis and Primary Psychiatric Psychosis.
     Neurology. 2022;98:e1489-e1498.
     PubMed     Abstract available
     
     
     
214. LEPPERT D, Kropshofer H, Haring DAA, Dahlke F, et al
     Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials.
     Neurology. 2022 Apr 4. pii: WNL.0000000000200258.
     PubMed     Abstract available
     
     
     March 2022
215. GALLAY L, Fermon C, Lessard L, Weiss-Gayet M, et al
     Involvement of Type-I Interferon Signaling in Muscle Stem Cell Proliferation During Dermatomyositis.
     Neurology. 2022 Mar 29. pii: WNL.0000000000200271.
     PubMed     Abstract available
     
     
     
216. PINAL-FERNANDEZ I, Greenberg SA
     Type I Interferons in Dermatomyositis Myoblasts: Toxic Effect and a Potential Autocrine Loop.
     Neurology. 2022 Mar 29. pii: WNL.0000000000200679.
     PubMed    
     
     
     
217. BOURDETTE D, Sormani MP
     Thinking Anew: Accelerating Clinical Trials of New Therapies for Progressive Multiple Sclerosis.
     Neurology. 2022 Mar 23. pii: WNL.0000000000200597.
     PubMed    
     
     
     
218. LI V, Leurent B, Barkhof F, Braisher M, et al
     Designing Multi-arm Multistage Adaptive Trials for Neuroprotection in Progressive Multiple Sclerosis.
     Neurology. 2022 Mar 23. pii: WNL.0000000000200604.
     PubMed     Abstract available
     
     
     
219. MOLIMARD A, Gitiaux C, Barnerias C, Audic F, et al
     Rituximab Therapy in the Treatment of Juvenile Myasthenia Gravis: The French Experience.
     Neurology. 2022 Mar 21. pii: WNL.0000000000200288.
     PubMed     Abstract available
     
     
     
220. BRIDEL C, Killestein J, Teunissen C
     Author Response: Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis.
     Neurology. 2022;98:471.
     PubMed    
     
     
     
221. KROPSHOFER H, Haring DA, Kappos L, Leppert D, et al
     Reader Response: Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis.
     Neurology. 2022;98:470-471.
     PubMed    
     
     
     
222. LEWIS A, Galetta S
     Editors' Note: Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis.
     Neurology. 2022;98:470.
     PubMed    
     
     
     
223. HUMMERT MW, Schoppe LM, Bellmann-Strobl J, Siebert N, et al
     Costs and Health-Related Quality of Life in Patients With NMO Spectrum Disorders and MOG-Antibody-Associated Disease: CHANCE(NMO) Study.
     Neurology. 2022;98:e1184-e1196.
     PubMed     Abstract available
     
     
     
224. SIMMONS SB, Ontaneda D
     Slowly Expanding Lesions: A New Target for Progressive Multiple Sclerosis Trials?
     Neurology. 2022 Mar 11. pii: WNL.0000000000200230.
     PubMed    
     
     
     
225. AZZOLINI F, Farina A, Gastaldi M, Barilaro A, et al
     Leptomeningeal Gadolinium Enhancement in Autoimmune GFAP-Astrocytopathy.
     Neurology. 2022 Mar 11. pii: WNL.0000000000200291.
     PubMed    
     
     
     
226. CALVI A, Carrasco FP, Tur C, Chard DT, et al
     Association of Slowly Expanding Lesions on MRI With Disability in People With Secondary Progressive Multiple Sclerosis.
     Neurology. 2022 Mar 11. pii: WNL.0000000000200144.
     PubMed     Abstract available
     
     
     
227. ZENG YH, Zhao M, Guo XX, Wang N, et al
     Cutaneous Lesions as a Clue to the Etiology of Extensive Intracranial Calcifications: Aicardi-Goutieres Syndrome.
     Neurology. 2022;98:417-418.
     PubMed    
     
     
     
228. LEVISON LS, Thomsen RW, Sindrup SH, Andersen H, et al
     Association Between Incident Cancer and Guillain-Barre Syndrome Development: A Nationwide Case-Control Study.
     Neurology. 2022 Mar 2. pii: WNL.0000000000200015.
     PubMed     Abstract available
     
     
     
229. HAMILTON RH, Ciccarelli O
     Non-White Participants Matter in White Matter Disease Studies: The Importance of Diversity in Multiple Sclerosis Clinical Trials.
     Neurology. 2022;98:345-346.
     PubMed    
     
     
     February 2022
230. MARZOUGHI S, Marulanda L, Ngo D, Chen T, et al
     Pearls & Oy-sters: Delayed Diagnosis of Acute Motor Axonal Neuropathy With Cardiac Arrest.
     Neurology. 2022;98:336-339.
     PubMed    
     
     
     
231. LIE IA, Weeda MM, Mattiesing RM, Mol MAE, et al
     Relationship Between White Matter Lesions and Gray Matter Atrophy in Multiple Sclerosis: A Systematic Review.
     Neurology. 2022 Feb 16. pii: WNL.0000000000200006.
     PubMed     Abstract available
     
     
     
232. MCELWEE DECKER B, Thibault D, Davis KA, Willis AW, et al
     Population-Based Study of Nonelective Postpartum Readmissions in Women With Stroke, Migraine, Multiple Sclerosis, and Myasthenia Gravis.
     Neurology. 2022 Feb 15. pii: WNL.0000000000200007.
     PubMed     Abstract available
     
     
     
233. HACOHEN Y, Ciccarelli O
     New Evidence for EBV Infection as a Cause of Multiple Sclerosis.
     Neurology. 2022 Feb 10. pii: WNL.0000000000200243.
     PubMed    
     
     
     
234. MAMMEN AL
     Inclusion Body Myositis: An Autoimmune or Myodegenerative Disease?
     Neurology. 2022 Feb 7. pii: WNL.0000000000200188.
     PubMed    
     
     
     
235. TORTORELLA C, Aiello A, Gasperini C, Agrati C, et al
     Humoral- and T-Cell-Specific Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different Disease-Modifying Therapies.
     Neurology. 2022;98:e541-e554.
     PubMed     Abstract available
     
     
     January 2022
236. ONUORAH HM, Charron O, Meltzer E, Montague A, et al
     Enrollment of Non-White Participants and Reporting of Race and Ethnicity in Phase III Trials of Multiple Sclerosis DMTs: A Systematic Review.
     Neurology. 2022 Jan 19. pii: WNL.0000000000013230.
     PubMed     Abstract available
     
     
     
237. CUTTER GR, Koch MW
     Multiple Sclerosis Diagnostic Criteria: Moving Ahead or Walking in Place?
     Neurology. 2022;98:12-13.
     PubMed    
     
     
     
238. FILIPPI M, Preziosa P, Meani A, Dalla Costa G, et al
     Performance of the 2017 and 2010 Revised McDonald Criteria in Predicting MS Diagnosis After a Clinically Isolated Syndrome: A MAGNIMS Study.
     Neurology. 2022;98:e1-e14.
     PubMed     Abstract available
     
     
     December 2021
239. DOETS AY, Lingsma HF, Walgaard C, Islam B, et al
     Predicting Outcome in Guillain-Barre Syndrome: International Validation of the Modified Erasmus GBS Outcome Score.
     Neurology. 2021 Dec 22. pii: WNL.0000000000013139.
     PubMed     Abstract available
     
     
     
240. MIRZA AI, Zhu F, Knox N, Forbes JD, et al
     Metagenomic Analysis of the Pediatric-Onset Multiple Sclerosis Gut Microbiome.
     Neurology. 2021 Dec 22. pii: WNL.0000000000013245.
     PubMed     Abstract available
     
     
     
241. COSTA AF, Rodriguez A, Martinez P, Blanco DCM, et al
     Teaching Video NeuroImage: Uncommon Neuro-ophthalmic Finding in a Patient With Miller Fisher Syndrome and Past SARS-CoV-2 Infection.
     Neurology. 2021;97:e2431-e2432.
     PubMed    
     
     
     
242. SHELLY S, Klein CJ, Dyck PJB, Paul P, et al
     Neurofascin-155 Immunoglobulin Subtypes: Clinicopathologic Associations and Neurologic Outcomes.
     Neurology. 2021;97:e2392-e2403.
     PubMed     Abstract available
     
     
     
243. SEBASTIAN P, Cherbuin N, Barcellos LF, Roalstad S, et al
     Association Between Time Spent Outdoors and Risk of Multiple Sclerosis.
     Neurology. 2021 Dec 8. pii: WNL.0000000000013045.
     PubMed     Abstract available
     
     
     
244. GRAVES JS, Killestein J
     Reading the "T" Leaves of COVID-19 Vaccine Responses in Multiple Sclerosis.
     Neurology. 2021 Dec 8. pii: WNL.0000000000013166.
     PubMed    
     
     
     
245. TANBOON J, Inoue M, Saito Y, Tachimori H, et al
     Dermatomyositis: Muscle Pathology According to Antibody Subtypes.
     Neurology. 2021 Dec 6. pii: WNL.0000000000013176.
     PubMed     Abstract available
     
     
     
246. NOWAK RJ, Coffey CS, Goldstein JM, Dimachkie MM, et al
     Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: The BeatMG Study.
     Neurology. 2021 Dec 2. pii: WNL.0000000000013121.
     PubMed     Abstract available
     
     
     November 2021
247. NEUPERT DG, Rathke KM, Mikati MA
     Teaching Video NeuroImage: Hereditary Hyperekplexia Mimicking Tonic Seizures in an Infant.
     Neurology. 2021;97:e2248-e2249.
     PubMed     Abstract available
     
     
     
248. TENCER J, Yum SW
     Teaching NeuroImage: Basal Ganglia T1 Hyperintensity and SWI Signal Diabetic Striatopathy in an 18-Year-Old Man With Type 1 Diabetes Mellitus.
     Neurology. 2021;97:e2148-e2149.
     PubMed    
     
     
     
249. DUMONCEAU AG, Ameli R, Rogemond V, Ruiz A, et al
     Glial Fibrillary Acidic Protein Autoimmunity: A French Cohort Study.
     Neurology. 2021 Nov 19. pii: WNL.0000000000013087.
     PubMed     Abstract available
     
     
     October 2021
250. 
     Patient-Reported Symptom Severity in a Nationwide Myasthenia Gravis Cohort: Cross-sectional Analysis of the Swedish GEMG Study.
     Neurology. 2021 Oct 29. pii: WNL.0000000000013021.
     PubMed    
     
     
     
251. AMATO A
     Author Response: Guillain-Barre Syndrome in the Placebo and Active Arms of a COVID-19 Vaccine Clinical Trial.
     Neurology. 2021;97:841-842.
     PubMed    
     
     
     
252. WILLER J
     Reader Response: Guillain-Barre Syndrome in the Placebo and Active Arms of a COVID-19 Vaccine Clinical Trial.
     Neurology. 2021;97:841.
     PubMed    
     
     
     
253. TINTORE M, Cobo-Calvo A, Carbonell P, Arrambide G, et al
     Effect of Changes in MS Diagnostic Criteria Over 25 Years on Time to Treatment and Prognosis in Patients With Clinically Isolated Syndrome.
     Neurology. 2021;97:e1641-e1652.
     PubMed     Abstract available
     
     
     
254. AA HOGLUND RA, Meyer HE, Stigum H, Torkildsen O, et al
     Association of Body Mass Index in Adolescence and Young Adulthood and Long-term Risk of Multiple Sclerosis: A Population-Based Study.
     Neurology. 2021 Oct 25. pii: WNL.0000000000012957.
     PubMed     Abstract available
     
     
     
255. KALINCIK T, Tremlett H, Ascherio A
     High BMI In Youths as a Modifiable Risk Factor for Multiple Sclerosis: Weighing Up the Evidence.
     Neurology. 2021 Oct 25. pii: WNL.0000000000012966.
     PubMed    
     
     
     
256. AGHAJAN Y, Mitchell RN, Bhattacharyya S, Hsu TY, et al
     Teaching NeuroImage: Bilateral Middle Cerebellar Peduncle Stroke in Giant Cell Arteritis.
     Neurology. 2021 Oct 19. pii: WNL.0000000000012953.
     PubMed    
     
     
     
257. JANDRIC D, Lipp I, Paling D, Rog D, et al
     Mechanisms of Network Changes in Cognitive Impairment in Multiple Sclerosis.
     Neurology. 2021 Oct 14. pii: WNL.0000000000012834.
     PubMed     Abstract available
     
     
     
258. SANCHEZ CV, Theel E, Binnicker M, Toledano M, et al
     Autoimmune Encephalitis Post-SARS-CoV-2 Infection: Case Frequency, Findings, and Outcomes.
     Neurology. 2021 Oct 11. pii: WNL.0000000000012931.
     PubMed     Abstract available
     
     
     
259. SIMPSON-YAP S, De Brouwer E, Kalincik T, Rijke N, et al
     Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis.
     Neurology. 2021 Oct 5. pii: WNL.0000000000012753.
     PubMed     Abstract available
     
     
     
260. KILLESTEIN J, Schoonheim MM, Voskuhl RR
     B-Cell Depletion and COVID-19 Severity in Multiple Sclerosis: Remaining Challenges.
     Neurology. 2021 Oct 5. pii: WNL.0000000000012754.
     PubMed    
     
     
     
261. BONACCHI R, Meani A, Pagani E, Marchesi O, et al
     Association of Age at Onset With Gray Matter Volume and White Matter Microstructural Abnormalities in People With Multiple Sclerosis.
     Neurology. 2021 Oct 4. pii: WNL.0000000000012869.
     PubMed     Abstract available
     
     
     
262. HACOHEN Y, Eshaghi A
     Multiple Sclerosis in Children and Adults: Does Age Matter?
     Neurology. 2021 Oct 4. pii: WNL.0000000000012866.
     PubMed    
     
     
     
263. VRENKEN H, Jenkinson M, Pham D, Guttmann CRG, et al
     Opportunities for Understanding MS Mechanisms and Progression With MRI Using Large-Scale Data Sharing and Artificial Intelligence.
     Neurology. 2021 Oct 4. pii: WNL.0000000000012884.
     PubMed     Abstract available
     
     
     September 2021
264. ZHAO-FLEMING HH, Valencia Sanchez C, Sechi E, Inbarasu J, et al
     CNS Demyelinating Attacks Requiring Ventilatory Support With Myelin Oligodendrocyte Glycoprotein or Aquaporin-4 Antibodies.
     Neurology. 2021;97:e1351-e1358.
     PubMed     Abstract available
     
     
     
265. MERLO D, Stankovich J, Bai C, Kalincik T, et al
     Association Between Cognitive Trajectories and Disability Progression in Patients With Relapsing-Remitting Multiple Sclerosis.
     Neurology. 2021 Sep 23. pii: WNL.0000000000012850.
     PubMed     Abstract available
     
     
     
266. MARRIE RA, Maxwell C, Mahar A, Ekuma O, et al
     Colorectal Cancer Survival in Multiple Sclerosis: A Matched Cohort Study.
     Neurology. 2021 Sep 15. pii: WNL.0000000000012634.
     PubMed     Abstract available
     
     
     
267. TOBIN O
     Early Diagnosis and Treatment is Associated With Improved Outcomes in Patients With Multiple Sclerosis.
     Neurology. 2021 Sep 14. pii: WNL.0000000000012738.
     PubMed    
     
     
     
268. CAMELO-FILHO AE, Estephan EP, Heise CO, Zanoteli E, et al
     Teaching Video NeuroImage: Reflex Facilitation in Lambert-Eaton Myasthenic Syndrome.
     Neurology. 2021;97:e1168-e1169.
     PubMed    
     
     
     
269. MILLER JW
     Inflammation As A Target For Epilepsy Therapy: The Case of Natalizumab.
     Neurology. 2021 Sep 14. pii: WNL.0000000000012768.
     PubMed    
     
     
     
270. GOLDSCHMIDT C, Fox RJ
     Relationship Between Serum Neurofilament Light and Multiple Sclerosis Disability Progression: Clear as Mud.
     Neurology. 2021 Sep 9. pii: WNL.0000000000012755.
     PubMed    
     
     
     
271. TOBIN WO, Kalinowska-Lyszczarz A, Weigand SD, Guo Y, et al
     Clinical Correlation of Multiple Sclerosis Immunopathologic Subtypes.
     Neurology. 2021 Sep 9. pii: WNL.0000000000012782.
     PubMed     Abstract available
     
     
     
272. BRIDEL C, Leurs CE, van Lierop ZY, van Kempen ZL, et al
     Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis.
     Neurology. 2021 Sep 9. pii: WNL.0000000000012752.
     PubMed     Abstract available
     
     
     
273. RADCLIFFE C, Potnis K, Peng TJ, DeCroce-Movson E, et al
     Teaching NeuroImage: Papilledema and Pachymeningitis: An Atypical Presentation of Granulomatosis With Polyangiitis.
     Neurology. 2021;97:e1060-e1061.
     PubMed    
     
     
     
274. YEH EA, Bourdette D, Wiendl H
     Longer-Term Safety of B-Cell Therapy With Ocrelizumab in Multiple Sclerosis.
     Neurology. 2021 Sep 2. pii: WNL.0000000000012716.
     PubMed    
     
     
     
275. HAUSER SL, Kappos L, Montalban X, Craveiro L, et al
     Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis.
     Neurology. 2021 Sep 2. pii: WNL.0000000000012700.
     PubMed     Abstract available
     
     
     
276. PALLADINO R, Chataway J, Majeed A, Marrie RA, et al
     Interface of Multiple Sclerosis, Depression, Vascular Disease, and Mortality: A Population-Based Matched Cohort Study.
     Neurology. 2021 Sep 1. pii: WNL.0000000000012610.
     PubMed     Abstract available
     
     
     
277. SALTER A
     Assessment of Biological Interactions Between MS Status and Depression for Mortality.
     Neurology. 2021 Sep 1. pii: WNL.0000000000012615.
     PubMed    
     
     
     August 2021
278. RICE J, Xiang XM
     Comparing the Effectiveness of Therapies in People With Secondary Progressive Multiple Sclerosis.
     Neurology. 2021;97:e972-e974.
     PubMed    
     
     
     
279. DOBSON R, Salter A
     Differing Impact of Disease-Modifying Therapy on Relapse and Progression: Time to Consider Inflammation and Neuroprotection Separately?
     Neurology. 2021;97:407-408.
     PubMed    
     
     
     
280. KOCH MW, Mostert JP, Wolinsky JS, Lublin FD, et al
     Comparison of the EDSS, Timed 25-Foot Walk, and the 9-Hole Peg Test as Clinical Trial Outcomes in Relapsing-Remitting Multiple Sclerosis.
     Neurology. 2021 Aug 25. pii: WNL.0000000000012690.
     PubMed     Abstract available
     
     
     
281. PETERSSON M, Feresiadou A, Jons D, Ilinca A, et al
     Patient-Reported Symptom Severity in a Nationwide Myasthenia Gravis Cohort: Cross-sectional Analysis of the Swedish GEMG Study.
     Neurology. 2021 Aug 10. pii: WNL.0000000000012604.
     PubMed     Abstract available
     
     
     
282. KOCH MW, Mostert J, Zhang Y, Wolinsky JS, et al
     Association of Age With Contrast-Enhancing Lesions Across the Multiple Sclerosis Disease Spectrum.
     Neurology. 2021 Aug 10. pii: WNL.0000000000012603.
     PubMed     Abstract available
     
     
     
283. FREY J, Kramer J, Castellani R, Sriwastava S, et al
     Clinical Reasoning: A 47-Year-Old With Headache, Vertigo, and Double Vision.
     Neurology. 2021;97:e535-e539.
     PubMed    
     
     
     
284. STRUPP M, Frenzel C, Goldschagg N, Halmagyi GM, et al
     Teaching Video NeuroImage: One Bedside Test, 2 Clinical Signs: One Vestibular, the Other Ocular Motor.
     Neurology. 2021;97:e541-e542.
     PubMed    
     
     
     July 2021
285. KARCESKI S
     Myasthenia Gravis: Which Type of Surgery Is Best?
     Neurology. 2021;97:e433-e435.
     PubMed    
     
     
     
286. CHEN T
     Clinical Reasoning: A 68-Year-Old Man With Proximal Weakness and Seizures.
     Neurology. 2021;97:e423-e428.
     PubMed    
     
     
     
287. SECHI E, Krecke KN, Messina SA, Buciuc M, et al
     Comparison of MRI Lesion Evolution in Different Central Nervous System Demyelinating Disorders.
     Neurology. 2021 Jul 14. pii: WNL.0000000000012467.
     PubMed     Abstract available
     
     
     
288. RASMINSKY M
     GCA Squared.
     Neurology. 2021;97:90-91.
     PubMed    
     
     
     
289. NICHOLAS RS, Rhone EE, Mariottini A, Silber E, et al
     Autologous Haematopoietic Stem Cell Transplantation in Active Multiple Sclerosis: a Real-world Case Series.
     Neurology. 2021 Jul 12. pii: WNL.0000000000012449.
     PubMed     Abstract available
     
     
     
290. LISAK RP
     [Editorial] At the Junction Where It Happens: Antibodies to LRP4 and Agrin Are Pathogenic in Myasthenia Gravis [re: M/S #2020/169756].
     Neurology. 2021 Jul 7. pii: WNL.0000000000012471.
     PubMed    
     
     
     
291. YU Z, Zhang M, Jing H, Chen P, et al
     Characterization of LRP4/Agrin Antibodies From a Patient with Myasthenia Gravis.
     Neurology. 2021 Jul 7. pii: WNL.0000000000012463.
     PubMed     Abstract available
     
     
     
292. HACOHEN Y, Kerr W, Waters P
     Intrathecal Production of MOG-IgG: Highlighting the Need for CSF Testing in Clinical Practice.
     Neurology. 2021;97:12-13.
     PubMed    
     
     
     
293. AKAISHI T, Takahashi T, Misu T, Kaneko K, et al
     Difference in the Source of Anti-AQP4-IgG and Anti-MOG-IgG Antibodies in CSF in Patients With Neuromyelitis Optica Spectrum Disorder.
     Neurology. 2021;97:e1-e12.
     PubMed     Abstract available
     
     
     
294. GUASP M, Gine-Serven E, Maudes E, Rosa-Justicia M, et al
     Clinical, Neuroimmunologic, and CSF Investigations in First Episode Psychosis.
     Neurology. 2021;97:e61-e75.
     PubMed     Abstract available
     
     
     June 2021
295. GRAY-RONCAL K, Fitzgerald K, Ryerson LZ, Charvet L, et al
     Association of Disease Severity and Socioeconomic Status in Black and White Americans With Multiple Sclerosis.
     Neurology. 2021 Jun 30. pii: WNL.0000000000012362.
     PubMed     Abstract available
     
     
     
296. ROOS I, Leray E, Casey R, Horakova D, et al
     Effects of High and Low Efficacy Therapy in Secondary Progressive Multiple Sclerosis.
     Neurology. 2021 Jun 30. pii: WNL.0000000000012354.
     PubMed     Abstract available
     
     
     
297. MYERS KA
     Author Response: Teaching Video NeuroImages: Pathologic Yawning: A Sign of Brainstem Involvement in Acute Disseminated Encephalomyelitis?
     Neurology. 2021;96:1105.
     PubMed    
     
     
     
298. FUJIMORI J, Nakashima I
     Reader Response: Teaching Video NeuroImages: Pathologic Yawning: A Sign of Brainstem Involvement in Acute Disseminated Encephalomyelitis?
     Neurology. 2021;96:1104-1105.
     PubMed    
     
     
     
299. VILLACIEROS-ALVAREZ J, Ordas CM, Torres-Gaona G, Diez-Barrio A, et al
     Teaching Video NeuroImages: Anti-IgLON5 Disease: A Long-Course Presentation With a Response to Immunotherapy.
     Neurology. 2021;96:e2901-e2902.
     PubMed    
     
     
     
300. HUISKAMP M, Eijlers AJC, Broeders TAA, Pasteuning J, et al
     Longitudinal Network Changes and Conversion to Cognitive Impairment in Multiple Sclerosis.
     Neurology. 2021 Jun 7. pii: WNL.0000000000012341.
     PubMed     Abstract available
     
     
     
301. PREZIOSA P, Schoonheim MM
     Ongoing Axonal Injury in Chronic Active Lesions in Multiple Sclerosis: In-Vivo Quantification Using Serum Neurofilament.
     Neurology. 2021 Jun 4. pii: WNL.0000000000012331.
     PubMed    
     
     
     
302. CAMPBELL CREE BA, Arnold DL, Chataway J, Chitnis T, et al
     Secondary Progressive Multiple Sclerosis: New Insights.
     Neurology. 2021 Jun 4. pii: WNL.0000000000012323.
     PubMed     Abstract available
     
     
     
303. MAGGI P, Kuhle J, Schadelin S, van der Meer F, et al
     Chronic White Matter Inflammation and Serum Neurofilament Levels in Multiple Sclerosis.
     Neurology. 2021 Jun 4. pii: WNL.0000000000012326.
     PubMed     Abstract available
     
     
     May 2021
304. SAN MARTIN AH, Cuadrado CA, Arbizu MG, Rabano-Suarez P, et al
     Autoimmune Septin-5 Disease Presenting as Spinocerebellar Ataxia and Nystagmus.
     Neurology. 2021 May 24. pii: WNL.0000000000012240.
     PubMed    
     
     
     
305. ROLLOT F, Fauvernier M, Uhry Z, Vukusic S, et al
     Effects of Age and Disease Duration on Excess Mortality in Patients With Multiple Sclerosis From a French Nationwide Cohort.
     Neurology. 2021 May 19. pii: WNL.0000000000012224.
     PubMed     Abstract available
     
     
     
306. MARRIE RA, Maxwell C, Mahar A, Ekuma O, et al
     Breast Cancer Survival in Multiple Sclerosis: A Matched Cohort Study.
     Neurology. 2021 May 19. pii: WNL.0000000000012127.
     PubMed     Abstract available
     
     
     
307. JOLLIFFE EA, Guo Y, Hardy TA, Morris PP, et al
     Clinical and Radiologic Features, Pathology, and Treatment of Balo Concentric Sclerosis.
     Neurology. 2021 May 19. pii: WNL.0000000000012230.
     PubMed     Abstract available
     
     
     
308. TOOSY AT, Kapur K, Nair KV
     Is OCT a Viable Tool to Monitor Disease-Modifying Treatments in RRMS Yet?
     Neurology. 2021;96:927-928.
     PubMed    
     
     
     
309. DAY GS, Yarbrough MY, Kortvelyessy P, Pruss H, et al
     Prospective Quantification of CSF Biomarkers in Antibody-Mediated Encephalitis.
     Neurology. 2021;96:e2546-e2557.
     PubMed     Abstract available
     
     
     
310. TITULAER MJ, Day GS
     Autoimmune Encephalitis in First Episode Psychoses: All Smoke and No Fire?
     Neurology. 2021 May 12. pii: WNL.0000000000012195.
     PubMed    
     
     
     
311. GIANNOCCARO MP, Liguori R
     Author Response: Comparison of Ice Pack Test and Single-Fiber EMG Diagnostic Accuracy in Patients Referred for Myasthenic Ptosis.
     Neurology. 2021;96:918-919.
     PubMed    
     
     
     
312. SILVESTRI N
     Reader Response: Comparison of Ice Pack Test and Single-Fiber EMG Diagnostic Accuracy in Patients Referred for Myasthenic Ptosis.
     Neurology. 2021;96:918.
     PubMed    
     
     
     
313. NERSESJAN V, McWilliam O, Krarup LH, Kondziella D, et al
     Autoimmune Encephalitis Related to Cancer Treatment With Immune Checkpoint Inhibitors: Systematic Review.
     Neurology. 2021 May 5. pii: WNL.0000000000012122.
     PubMed     Abstract available
     
     
     
314. 
     Long-term Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis.
     Neurology. 2021 May 4. pii: WNL.0000000000011825.
     PubMed    
     
     
     
315. SOLIS-PAZMINO P, Baiu I, Lincango-Naranjo E, Trope W, et al
     Impact of the Surgical Approach to Thymectomy Upon Complete Stable Remission Rates in Myasthenia Gravis: A Meta-analysis.
     Neurology. 2021 May 4. pii: WNL.0000000000012153.
     PubMed     Abstract available
     
     
     
316. FOX RJ, Kryscio RJ
     A New Way to Identify Promising Therapies for Progressive Multiple Sclerosis.
     Neurology. 2021;96:833-834.
     PubMed    
     
     
     
317. KOCH MW, Sage K, Kaur S, Kim J, et al
     Repurposing Domperidone in Secondary Progressive Multiple Sclerosis: A Simon 2-Stage Phase 2 Futility Trial.
     Neurology. 2021;96:e2313-e2322.
     PubMed     Abstract available
     
     
     
318. BAR-OR A, Herman A, Stokmaier D
     Author Response: Effect of Ocrelizumab on Vaccine Responses in Patients With Multiple Sclerosis: The VELOCE Study.
     Neurology. 2021;96:870.
     PubMed    
     
     
     
319. HAHN N
     Reader Response: Effect of Ocrelizumab on Vaccine Responses in Patients With Multiple Sclerosis: The VELOCE Study.
     Neurology. 2021;96:870.
     PubMed    
     
     
     
320. SIEGLER JE, Galetta S
     Editors' Note: Effect of Ocrelizumab on Vaccine Responses in Patients With Multiple Sclerosis: The VELOCE Study.
     Neurology. 2021;96:869.
     PubMed    
     
     
     April 2021
321. DUBESSY AL, Tezenas du Montcel S, Viala F, Assouad R, et al
     Association of Central Hypersomnia and Fatigue in Patients With Multiple Sclerosis: A Polysomnographic Study.
     Neurology. 2021 Apr 30. pii: WNL.0000000000012120.
     PubMed     Abstract available
     
     
     
322. ZOUVELOU V, Daponte A
     Teaching Video NeuroImages: Resolution of Ptosis After Forceful Eye Closure: Bedside Diagnosis of Myasthenia Gravis.
     Neurology. 2021 Apr 30. pii: WNL.0000000000012100.
     PubMed    
     
     
     
323. LEAVITT VM, Dobson R, Svennigsson A
     Perinatal Depression and Anxiety in Multiple Sclerosis: Treatable Distress.
     Neurology. 2021 Apr 28. pii: WNL.0000000000012101.
     PubMed    
     
     
     
324. SHELLY S, Mills JR, Dubey D, McKeon A, et al
     Clinical Utility of Striational Antibodies in Paraneoplastic and Myasthenia Gravis Paraneoplastic Panels.
     Neurology. 2021 Apr 26. pii: WNL.0000000000012050.
     PubMed     Abstract available
     
     
     
325. SALAVISA M, Serrazina F, Pires P, Correia AS, et al
     Teaching Video NeuroImages: Infratentorial Multiple Sclerosis Relapse Presenting as Continuous Hemifacial Myokymia.
     Neurology. 2021 Apr 26. pii: WNL.0000000000012052.
     PubMed    
     
     
     
326. GASPERI C, Hapfelmeier A, Daltrozzo T, Schneider A, et al
     Systematic Assessment of Medical Diagnoses Preceding the First Diagnosis of Multiple Sclerosis.
     Neurology. 2021 Apr 26. pii: WNL.0000000000012074.
     PubMed     Abstract available
     
     
     
327. SOLOMON AJ, Ascherio A
     Early Diagnosis of Multiple Sclerosis: Further Evidence for Missed Opportunity.
     Neurology. 2021 Apr 26. pii: WNL.0000000000012087.
     PubMed    
     
     
     
328. 
     Association of Gray Matter Atrophy Patterns With Clinical Phenotype and Progression in Multiple Sclerosis.
     Neurology. 2021 Apr 23. pii: WNL.0000000000012021.
     PubMed    
     
     
     
329. EID K, Torkildsen OF, Aarseth J, Flemmen HO, et al
     Perinatal Depression and Anxiety in Women with Multiple Sclerosis: A Population-Based Cohort Study.
     Neurology. 2021 Apr 21. pii: WNL.0000000000012062.
     PubMed     Abstract available
     
     
     
330. YEH WZ, Widyastuti PA, Van der Walt A, Stankovich J, et al
     Natalizumab, Fingolimod and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis.
     Neurology. 2021 Apr 20. pii: WNL.0000000000012084.
     PubMed     Abstract available
     
     
     
331. SHELLY S, Shouman K, Paul P, Engelstad J, et al
     Expanding the Spectrum of Chronic Immune Sensory Polyradiculopathy: CISP-Plus.
     Neurology. 2021;96:e2078-e2089.
     PubMed     Abstract available
     
     
     
332. NISHIDA H, Kohyama K, Kumada S, Takanashi JI, et al
     Evaluation of the Diagnostic Criteria for Anti-NMDA Receptor Encephalitis in Japanese Children.
     Neurology. 2021;96:e2070-e2077.
     PubMed     Abstract available
     
     
     
333. COLLONGUES N, Alves Do Rego C, Bourre B, Biotti D, et al
     Pregnancy in Patients With AQP4-Ab, MOG-Ab, or Double-Negative Neuromyelitis Optica Disorder.
     Neurology. 2021;96:e2006-e2015.
     PubMed     Abstract available
     
     
     
334. LAMBE J, Risher H, Filippatou AG, Murphy OC, et al
     Modulation of Retinal Atrophy With Rituximab in Multiple Sclerosis.
     Neurology. 2021 Apr 7. pii: WNL.0000000000011933.
     PubMed     Abstract available
     
     
     
335. BOURDETTE D, Killestein J
     Quelling Public Fears about Guillain-Barre Syndrome and COVID-19 Vaccination.
     Neurology. 2021 Apr 6. pii: WNL.0000000000011882.
     PubMed    
     
     
     
336. MARQUEZ LOZA AM, Holroyd KB, Johnson SA, Pilgrim DM, et al
     Guillain- Barre Syndrome in the Placebo and Active Arms of a COVID-19 Vaccine Clinical Trial: Temporal Associations Do Not Imply Causality.
     Neurology. 2021 Apr 6. pii: WNL.0000000000011881.
     PubMed    
     
     
     
337. ALLEN JA, Pasnoor M, Dimachkie MM, Ajroud-Driss S, et al
     Quantifying Treatment-Related Fluctuations in CIDP: Results of the GRIPPER Study.
     Neurology. 2021;96:e1876-e1886.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Autoimmune Disorders is free of charge.